Ireland - English - HPRA (Health Products Regulatory Authority)

alcon laboratories (uk) ltd - dexamethasone, polymyxin b sulfate, neomycin sulfate - eye drops suspension - %w/v - corticosteroids and antiinfectives in combination

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - neomycin sulfate, polymyxin b sulfate, dexamethasone - eye ointment - corticosteroids and antiinfectives in combination

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - dexamethasone, polymyxin b sulfate, neomycin sulfate - eye drops suspension - %w/v - corticosteroids and antiinfectives in combination

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - dexamethasone; hypromellose; neomycin sulfate; polymyxin b sulfate - eye drops - 1mg/1ml ; 5mg/1ml ; 3500unit/1ml ; 6000unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - dexamethasone; neomycin sulfate; polymyxin b sulfate - eye ointment - 1mg/1gram ; 3500unit/1gram ; 6000unit/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - dexamethasone; polymyxin b sulfate; neomycin sulfate - eye drops, suspension - 0.1% w/v, 6000 iu/ml, 3500 iu/ml percent weight/volume - corticosteroids and antiinfectives in combination; dexamethasone and antiinfectives

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - tramadol hydrochloride - modified-release capsule - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - tramadol hydrochloride - modified-release capsule - 150mg

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus   influenzae , klebsiella /

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae , klebsiella